Sun Pharma Q4 results today: Net profit likely to rise, final dividend expected; check earnings preview

Pharma major, Sun Pharmaceutical Industries, will announce its March quarter results today. The results are expected to be announced after market hours followed by analyst/ investor meeting.

In the December (Q3FY25) quarter, Sun Pharma registered a consolidated net profit of ₹2,913 crore, up 13% YoY, while its revenue from operations stood at ₹13,675 crore, up 10% YoY during the same period. The company reported revenue of ₹11,983 crore in Q4FY24 and net profit of ₹2,659 crore.

According to experts, Sun Pharma could report double-digit growth in revenue and net profit for the March quarter. Its profitability could rise 15-18% YoY to ₹2,900 to ₹3,100 crore, while revenue could increase by 10-14% YoY to ₹12,550 to ₹13,750 crore.

Sun Pharma shares have given subdued returns to investors so far in 2025. The stock is down over 8.5% this year and 6% in May 2025. US trade tariff threats have impacted the Sun Pharma stock performance.

EBITDA margin is expected to improve on the back of higher sales of the Revlimid, gRevlimid, and Taro pharm drug and sustained growth in domestic formulations.

What should investors look forward to?

During the quarterly result announcement, investors should monitor key financial metrics and management commentary on the US business and the impact of US trade tariffs. Investors will also look forward to dividend announcements.